Christiana Stamoulis : So I can take the first part of the question. No, we don’t expect any difference in gross to net between the two indications.
Barry Flannelly : So in terms of difference between compliance rates, no, we don’t expect difference. As I said before, in vitiligo, we believe that the average will be about 10 tubes per year. So obviously, these patients are staying on it for a long period of time, as long as 52 weeks and beyond. And in terms of AD, patients use it until their inflammation and itch is gone, then they generally will stop for a while. If their flare comes back, their itching comes back, their inflammation comes back, then they’ll start using it again. So I believe they’re compliant. It’s just different diseases, obviously, some needing short-term use and some like vitiligo that are going to use it probably for a long period of time.
Tazeen Ahmad : And have you noticed any seasonality during holidays?
Barry Flannelly : Well, seasonality during holidays. Well, in holidays, generally across the board — for all of our products generally during holidays, like Christmas and Thanksgiving, for example, you see prescription rates go down. But in terms of summer versus winter, we don’t see any difference now and don’t believe that there’s really any evidence that there’s a difference in seasonality for AD or for vitiligo. Amongst individual patients, they may perceive the difference being — that there’s differences in the summer versus winter and so forth.
Operator: Next question is coming from Vikram Purohit from Morgan Stanley.
Vikram Purohit : The two on dermatology from our side. First, for the Phase 3 data expected later this year for RUX cream in the pediatric AD population, what would you consider a strong outcome here? And how do you size the commercial opportunity with the pediatric population versus the adult population? And then my second question is on povorcitinib. For the data expected in the first half of this year with vitiligo, again, what would you consider a good outcome? And how do you envision povorcitinib being used if it’s potentially approved versus Opzelura?
Steven Stein : Vikram, hi. It’s Steven. So the pediatric atopic dermatitis study, as Barry said in his prepared remarks, addresses a population from two years of age up to 11 years of age. So outside the label currently, so — and that it’s important. That’s about 2 million patients in the U.S. in terms of epidemiology and the opportunity there. Safety-wise, we expect — so efficacy-wise, firstly, we expect it to be the same as in adults. There’s no reason — the pathophysiology of the disease is the same, and we expect the same outcomes. And then safety-wise, we don’t expect anything unusual either. They separate the populations out for obvious reasons like this is a time when bone growth, et cetera, is occurring. So there are other things that are monitored from a safety perspective.
But from our preclinical data and then data with oral RUX, which is at much higher exposures in pediatric patients, we don’t expect anything unusual there. In povorcitinib, your second question in vitiligo, it’s a different population to the RUX cream population. There is a slight overlap, but the povorcitinib indication that we go in after it is for patients with body surface area involvement of 8% or above. The current vitiligo label is 10% or below body surface area involvement, which compromises about 80% of vitiligo patients. Because of the slight overlap, it’s not straight math, but the 8% or above is about 30% of vitiligo patients. And there, we think because of the more extensive vitiligo there, there will obviously be a different tolerability profile that would be accepted by patients and regulators in terms of therapeutic ratio.
